Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROSTVAC in metastatic castrate-resistant prostate cancer
NCT01322490Phase 3Completed
- Sponsor
- Bavarian Nordic
- Start
- Nov 2011
- Primary completion
- Sep 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 16
01
Overview
A Phase 3 trial of PROSTVAC-TRICOM in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Bavarian Nordic. Started Nov 2011; status: completed.
02
Drugs
PROSTVAC-TRICOM
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01322490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01322490.